



For adults living with human immunodeficiency virus (HIV)

If you are living with HIV and are looking for an alternative to standard treatment, the EMBRACE Study may interest you.

WHAT IS THE EMBRACE STUDY TESTING?

This study is being done to learn more about the study drug, VH3810109, in combination with cabotegravir (CAB), a medicine already approved for HIV. Researchers want to see whether the combination of these 2 drugs can maintain a low amount of HIV virus inside the body.

This study will compare the effects of the study drug with those of the current standard treatment for HIV.

WHO CAN JOIN THE STUDY?

This study is for adults*:

- 18 to 70 years of age.
- Diagnosed with HIV-1.
- Taking standard treatment for HIV for at least 6 months.
- Who have had a successful response to current HIV treatment.

*Other criteria also apply.

WHAT HAPPENS DURING THE STUDY?

- To determine whether you qualify, the study doctor will collect information about your health and run some tests.
- If you qualify, you'll be placed by chance into a group to receive either the study drug + CAB or standard HIV treatment for 2 years. Your chances of receiving the study drug are 4 times greater than your chances of receiving standard treatment.
- You will have visits at the study site for treatment and tests to check on your health.

PARTICIPATION IN A CLINICAL STUDY IS VOLUNTARY.

You can choose to stop participating at any time.

For more information about the EMBRACE Study, contact:



Scan the code or visit
Embracestudy.viiv.com

PIN: 2096